Tanshinone IIA Inhibits Cervix Carcinoma Stem Cells Migration and Invasion Via Inhibiting YAP Transcriptional Activity
Overview
General Medicine
Pharmacology
Affiliations
This study aims to explore the effects and related mechanisms of Tanshinone IIA in cervix carcinoma (CC) stemness-like cells migration, invasion, stemness and chemotherapeutical sensitivity. Here, we found that Tanshinone IIA suppressed CC stemness-like cells migration and invasion in a concentration- and time-dependent manner. And consistent results were obtained in CC cells stemness characterized as the decrease of CC stemness markers expression and cells spheroid formation ability. Mechanistically, we found that Tanshinone IIA suppressed RNA binding protein HuR translocation from nuclear to cytoplasm, and thus reduced YAP mRNAs stability and transcriptional activity. Importantly, overexpression YAP-5SA rescued the inhibition of Tanshinone IIA on CC cells stemness. Furthermore, Tanshinone IIA enhanced adriamycin sensitivity in CC stemness-like cells, this effect was attenuated by YAP-5SA overexpression too. Therefore, Tanshinone IIA could suppress CC stemness-like cells migration and invasion by inhibiting YAP transcriptional activity.
Shahrokhi H, Asili J, Tayarani-Najaran Z, Boozari M Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 39937254 DOI: 10.1007/s00210-025-03857-x.
The mechanisms of tanshinone in the treatment of tumors.
Zhang P, Liu W, Wang Y Front Pharmacol. 2023; 14:1282203.
PMID: 37964867 PMC: 10642231. DOI: 10.3389/fphar.2023.1282203.
An overview of the anti-cancer actions of Tanshinones, derived from (Danshen).
Naz I, Merarchi M, Ramchandani S, Khan M, Malik M, Sarwar S Explor Target Antitumor Ther. 2022; 1(3):153-170.
PMID: 36046197 PMC: 9400791. DOI: 10.37349/etat.2020.00010.
Anticancer Effect of Tanshinones on Female Breast Cancer and Gynecological Cancer.
Jin Z, Chenghao Y, Cheng P Front Pharmacol. 2022; 12:824531.
PMID: 35145409 PMC: 8822147. DOI: 10.3389/fphar.2021.824531.
Li X, Jia Q, Zhou Y, Jiang X, Song L, Wu Y Exp Hematol Oncol. 2022; 11(1):2.
PMID: 35057866 PMC: 8781032. DOI: 10.1186/s40164-022-00255-4.